Results 51 to 60 of about 11,202 (179)

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Secretin-dependent signals in the ventromedial hypothalamus regulate energy metabolism and bone homeostasis in mice

Nature Communications
Secretin, though originally discovered as a gut-derived hormone, is recently found to be abundantly expressed in the ventromedial hypothalamus, from which the central neural system controls satiety, energy metabolism, and bone homeostasis.
Fengwei Zhang, Wei Qiao, Ji-an Wei, Zhengyi Tao, Congjia Chen, Yefeng Wu, Minghui Lin, Ka Man Carmen Ng, Li Zhang, Kelvin Wai-Kwok Yeung, Billy Kwok Chong Chow   +10 more
doaj   +1 more source

Involvement of Secretin in the Control of Cell Survival and Synaptic Plasticity in the Central Nervous System

Frontiers in Neuroscience, 2020
With emerging evidence showing a wide distribution of secretin (SCT) and its receptor (SCTR) in the central nervous system (CNS), the putative neuropeptide role of SCT has become more appreciated since the disruption of SCT/SCTR axis affects various ...
Lei Wang, Li Zhang
doaj   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano, Line L. Haurum, Christine R. Schwarz, Francesca Porcellati, Andreas Andersen   +4 more
wiley   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

Obesity Reviews, EarlyView.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani, Tzu‐Wen L. Cross, Erica de Jong, Emily S. Glover, Ivan D. Mendoza, Mojisola Adisa, Keigo Tomoo, Xinyi Zhou, Richard D. Mattes   +8 more
wiley   +1 more source

Drugs that act on both G protein‐coupled receptors (GPCRs) and kinases: potentiation of effects, side effects and general aspects of drug pleiotropy

British Journal of Pharmacology, Volume 183, Issue 13, Page 3471-3483, July 2026.
Abstract Background A drug designed for a specific target often interacts with multiple targets, either unintentionally or as part of its intended mechanism of action. This has been called pharmacological pleiotropy or polypharmacology. There are key endogenous ligands such as ATP, GABA and glutamate that act on various proteins in humans. Furthermore,
Hampus Ljunggren, Aleksandr Sokolov, Flavio Ballante, Robert Fredriksson, Francisco Lagunas‐Rangel, Alexander S. Hauser, Stefan Knapp, Jörgen Jonsson, Helgi B. Schiöth   +8 more
wiley   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Corticotropin-Releasing Factor: An Ancient Peptide Family Related to the Secretin Peptide Superfamily

Frontiers in Endocrinology, 2020
Corticotropin-releasing factor (CRF) is the hypothalamic releasing peptide that regulates the hypothalamic-pituitary-adrenal/inter-renal (HPA/I) axis in vertebrates.
Ola M. Michalec, Belinda S. W. Chang, Nathan R. Lovejoy, David A. Lovejoy   +3 more
doaj   +1 more source

The Duodenal Mucosa Plays a Key Role in Metabolic Regulation: Emerging Physiology and New Opportunities for Cell‐Directed and Barrier‐Related Interventions for the Treatment of Diabetes and Obesity

Diabetes, Obesity and Metabolism, Volume 28, Issue S3, Page 3-15, June 2026.
ABSTRACT The duodenum has historically been regarded as a passive digestive conduit for nutrient transit and absorption. However, emerging experimental and clinical evidence supports a revision of this view. In a contemporary model, the proximal small intestine also has roles as a metabolic sensor and endocrine signalling hub that exerts a powerful ...
David A. D’Alessio, Jonathan E. Campbell   +1 more
wiley   +1 more source

The role of opioid peptides in the regulation of secretin-stimulated bile secretion

Бюллетень сибирской медицины, 2006
Influence of intraperitoneal dalargin (dand m-opioid agonist), DADLE (d-opioid agonist), DAGO (m-opioid agonist) and U50488 (k-opioid agonist) on bile secretion which is stimulated by secretin was studied in sharp experiments on white rats.
M. A. Medvedev, I. V. Roudin
doaj   +1 more source